Brian Rye

Health Industries Senior Manager with @PwC Intelligence. Formerly with @Bloomberg, @SunTrust, @RaymondJames, @Janney1832. @VanderbiltU alum; Tweets are my own.

[⟠ degenbing.eth 🦄 @degenbing_eth]

All unclaimed tokens will be burned by 4:00PM EST 6/25/2023 ‼

Claim your $APE now 👇
🔗https://t.co/RAi9xRCS7Y

#100x #SHIB #Blockchain #DOGE $BNB #ben Floki #NFTs $link #DeFi $MANA $hex #PEPE Arbitrum $BEN $xrp $PSYOP #binance $btc $ADA #LUNC $pepe #bullrun #100X

[Adam Mery @AdamMeryETH]

GM FAM 🧡, ready to claim your $LOYAL airdrop? ‼

Check eligibility and claim on:
🔗https://t.co/MQT4c9H8ou

Arbitrum #LUNC #100x #NFTs $xrp $PSYOP #100X #SHIB $ADA $link $hex #bullrun $btc #Blockchain #ben $pepe $BNB $BEN $MANA #DOGE Floki #binance #DeFi #PEPE

[Brian Rye @Brian_Rye]

👇$GPEPE wil smoke bob and pepe first day of listing💰👢II $PEPE $BOB $JESUS $AIDOGE $PSALE $SUI $MONG $ETH $BTC $GMFAM $XRP $PSYOP $RFD

[Brian Rye @Brian_Rye]

👇 $GPEPE will flip #PEPE marketcap today💰👢II ! $PEPE $BOB $JESUS $AIDOGE $PSALE $SUI $MONG $ETH $BTC $GMFAM $XRP $PSYOP $RFD

[Brian Rye @Brian_Rye]

👇 $GPEPE will be bigger then all this trash meme coins!🚀💰 $PEPE $BOB $JESUS $AIDOGE $PSALE $SUI $MONG $ETH $BTC $GMFAM $XRP $PSYOP $RFD

[Brian Rye @Brian_Rye]

👇Just got my $GPEPE airdrop, listing will happen today! This one will do 500X for sure! 👢II $PEPE $BOB $JESUS $AIDOGE $PSALE $SUI $MONG $ETH $BTC $GMFAM $XRP $PSYOP $RFD

[Brian Rye @Brian_Rye]

👇 Thank you i just got my $GPEPE airdrop lets goooo 👢II 💰 $PEPE $BOB $JESUS $AIDOGE $PSALE $SUI $MONG $ETH $BTC $GMFAM $XRP $PSYOP $RFD

[Brian Rye @Brian_Rye]

@CLeuthy @BGOV My disbelief that you’re 65 is eclipsed only by my happiness for you. Enjoy the next chapter; you’ve earned it!

[Brian Rye @Brian_Rye]

@Andy_Ryan_dydx @Health_Affairs @AdamMarkovitz @jzayanian @awarrier1221 Really enjoyed reading this thorough report, Andrew. I’m curious if CMS publishes list of these double-bonus counties.

[Brian Rye @Brian_Rye]

@caitlinwebber @Reuters Congratulations, Caitlin!

[Jeff Stein @jstein_notus]

Scoop: White House budget will NOT include key Biden campaign pledges -- such as the public option, prescription drugs reform, or student debt relief, per sources

WH squarely focused on $4T in jobs/infrastructure + "families" plans

W/ @tylerpager

https://t.co/3DJIQfYPi6

[InsideHealthPolicy @InHealthPolicy]

Biden CMS Rewriting Trump CMS’ Medicaid Best Price Rule https://t.co/UnhPKjDlcX

[Alex Ruoff @Alexruoff]

There's about $25B left in the provider relief fund, @SecBecerra says, plus $8B for rural providers.

There's been some uncertainty about how much is left.

[Rachel Cohrs Zhang @rachelcohrs]

Fantastic @NicholasFlorko story on the sudden rush of off-cycle campaign cash to pharma industry ally Sen. Bob Menendez. Illustrates that executives view the Senate as the true drug pricing battleground https://t.co/vbnSu4z4li @statnews

[Peter Sullivan @PeterSullivan4]

Biden’s families plan leaves out both lowering drug prices and lowering the Medicare eligibility age, despite pressure from hill D’s ranging from Jared Golden to Pramila Jayapal https://t.co/mP5xGDIDB3

[Rachel Cohrs Zhang @rachelcohrs]

Notable bipartisan letter here from House Energy & Commerce leaders asking HHS Secretary Xavier Becerra to crack down on hospitals' noncompliance with Trump-era price transparency rules https://t.co/IybFDlg7vR

[Peter Sullivan @PeterSullivan4]

New story: Dems planning major push to lower drug prices as part of infrastructure bill

Including HR3 is priority for House Dem leaders

Some doubts about the votes in the Senate though

https://t.co/Ht9DOrn6vn

[Rachel Cohrs Zhang @rachelcohrs]

New: In a lobbying win for hospitals, Senate leaders have reached a deal to extend Medicare pay bumps through the end of 2021, per bill text obtained by STAT. Senate Majority Leader Schumer said there are plans for the Senate to vote this week
https://t.co/z3xvKQHLB5
@statnews

[Brian Rye @Brian_Rye]

@PeterSullivan4 Repealing the Part D noninterference clause is tough to do with such a slim Dem majority, especially as it is one of the few policy provisions where the interests of pharma and PBMs/insurers/generics are aligned. None of them want the government negotiating/dictating prices.